ReviewFood science & nutrition2026
The Dietary Polyphenol Resveratrol in Intestinal Ischemia-Reperfusion Injury: From Multifaceted Protective Mechanisms to Clinical Translation Challenges.
Review in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal ischemia-reperfusion (I/R) injury constitutes a life-threatening condition with mortality approaching 50%, yet effective therapeutic interventions remain limited. Resveratrol, a natural polyphenolic compound, has demonstrated promising multi-targeted protective effects in preclinical models by simultaneously enhancing antioxidant defense, suppressing inflammatory cascades, inhibiting ferroptosis, stabilizing mast cells, and preserving intestinal barrier integrity through SIRT1/SIRT3-mediated pathways. Novel delivery systems, including exosome-based carriers and nanoformulations, have shown enhanced therapeutic efficacy in overcoming bioavailability limitations. However, a critical translational gap persists between experimental promise and clinical reality. Three interconnected obstacles impede progress: the complete absence of human clinical trials in intestinal I/R contexts, poor pharmacokinetics characterized by extensive first-pass metabolism that raises fundamental questions about achievable therapeutic tissue concentrations, and the lack of large animal validation studies bridging rodent models and human pathophysiology. This review provides critical analysis of evidence quality, identifies specific knowledge gaps, and proposes a structured translational roadmap prioritizing clinically relevant post-ischemic treatment paradigms, comprehensive pharmacokinetic characterization, biomarker development, and proof-of-concept clinical trials to advance resveratrol toward clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.